Low-T / hypogonadism / TRT support

hCG is a structural analog of LH and binds the Leydig-cell LH receptor, directly driving endogenous intratesticular testosterone (ITT) production. This matters because exogenous TRT suppresses pituitary LH/FSH and collapses ITT (which normally runs ~50-100x serum levels), the very thing spermatogenesis depends on; hCG substitutes the missing LH signal to hold ITT up while serum T is being replaced.

Strong for the fertility-preservation lever. A randomized dose-response RCT in men with T-induced gonadotropin suppression showed low-dose hCG (as little as 250 IU every other day) maintains ITT in the normal range (Coviello 2005, PMID 15713727) - note this is a short (3-week) surrogate-endpoint study in men with normal reproductive physiology, not a fertility-outcome trial. A retrospective series of hypogonadal men on TRT plus 500 IU intramuscular hCG every other day preserved semen parameters with no azoospermia and documented 9/26 pregnancies (Hsieh 2013, PMID 23260550; mean follow-up ~6 months). Contemporary reviews support hCG both for secondary hypogonadism and as a TRT co-therapy (Fink 2021, PMID 33345656; Esteves 2025, PMID 39901824). The grade is confirmed strong for ITT maintenance/fertility preservation; hard fertility-outcome RCTs in older TRT populations remain limited.

Anecdotal community signal (not proof): TRT users very widely co-run hCG to prevent testicular atrophy, preserve fertility, and reportedly maintain libido and a 'sense of fullness' that some feel is lost on TRT alone. Common self-reported regimens are low-dose subcutaneous microdosing rather than large intramuscular boluses. Some report reversal of testicular shrinkage within weeks; over-dosing is anecdotally linked to acne, moodiness, and estradiol spikes. None of these self-reports are controlled evidence.

Context, not a protocol: published/clinical ranges cluster around 250-500 IU two to three times weekly (or every other day) alongside TRT; monotherapy for secondary hypogonadism has used higher ranges (e.g. 1500-3000 IU 2-3x/week). Lower, more frequent subcutaneous dosing is favored to limit estradiol conversion.

hCG stimulates aromatization, so it can raise estradiol and may require monitoring or an aromatase inhibitor in sensitive men. It requires functional Leydig cells, so it is ineffective in primary (testicular) hypogonadism. Real-world US supply has been disrupted by FDA restrictions on compounded hCG, pushing some clinicians toward gonadorelin/enclomiphene alternatives. Contraindicated where androgen stimulation is unwanted (e.g. active androgen-sensitive prostate cancer).

• Low-dose human chorionic gonadotropin maintains intratesticular testosterone in normal men with testosterone-induced gonadotropin suppression. ↗
• Concomitant intramuscular human chorionic gonadotropin preserves spermatogenesis in men undergoing testosterone replacement therapy. ↗
• Human chorionic gonadotropin treatment: a viable option for management of secondary hypogonadism and male infertility. ↗
• Human chorionic gonadotropin-based clinical treatments for infertile men with non-obstructive azoospermia. ↗

Gonadorelin is identical to native GnRH and stimulates pituitary gonadotropes to release LH and FSH; because GnRH signaling is pulsatile by design, physiologic effect requires pulsatile delivery (a pump), whereas continuous exposure paradoxically desensitizes and suppresses the axis. Restoring both LH and FSH (unlike hCG, which supplies only LH-like activity) engages the full upstream axis and can support both testosterone and spermatogenesis.

Emerging. The strongest data are in CHH: a nonrandomized comparative study (n=28) found a pulsatile gonadorelin pump induced spermatogenesis earlier (median 6 vs 14 months) with more physiologic testosterone and fewer supraphysiologic side effects than cyclical hCG/hMG (Zhang 2018, PMID 30569789), consistent with mechanistic reviews of GnRH-deficiency treatment (Pitteloud 2014, PMID 24793994). There is no comparable trial evidence for the way gonadorelin is increasingly used in general TRT clinics (intermittent subcutaneous injection as an hCG substitute); that application is mechanistically plausible but essentially unstudied, so the emerging grade is confirmed and should not be over-read.

Anecdotal community signal (not proof): since compounded hCG became hard to obtain in the US, TRT clinics and users have adopted gonadorelin as a convenient hCG stand-in, injected subcutaneously a few times weekly to 'keep the testes on.' Users report preserved testicular size and libido, but many also report it feels weaker/shorter-acting than hCG (gonadorelin has a very short half-life of minutes), and dosing is largely empirical rather than truly pulsatile. These are uncontrolled reports, not evidence of efficacy.

Context, not a protocol: the validated CHH approach uses a pump delivering micro-boluses roughly every 90-120 minutes. Real-world TRT use is entirely different, typically small subcutaneous doses (commonly cited in the 100-200 mcg range) 2-3x weekly or more often, chosen for convenience rather than evidence.

Efficacy depends on an intact pituitary and Leydig cells, so it fails in primary hypogonadism and pituitary failure. The pharmacology cuts against convenience: its ultrashort half-life means intermittent injections do not reproduce physiologic pulsatility, and continuous/too-frequent exposure risks downregulating the very receptors it targets. Like hCG it can raise estradiol via increased endogenous testosterone.

• The Pulsatile Gonadorelin Pump Induces Earlier Spermatogenesis Than Cyclical Gonadotropin Therapy in Congenital Hypogonadotropic Hypogonadism Men. ↗
• Hormonal control of spermatogenesis in men: therapeutic aspects in hypogonadotropic hypogonadism. ↗

Kisspeptin (via the KISS1R/GPR54 receptor) is the master trigger for GnRH neuron firing, sitting one level above GnRH in the reproductive axis and integrating metabolic signals with reproduction. The therapeutic idea is that in central/metabolic hypogonadism the GnRH pulse generator is under-driven, and kisspeptin can restore hypothalamic drive, increasing endogenous LH pulsatility and downstream testosterone, potentially with more preserved physiologic feedback than exogenous LH.

Emerging, and thin. Human data are small mechanistic proof-of-concept studies: an IV kisspeptin-10 study in hypotestosteronaemic men with type 2 diabetes (n=5) increased LH pulse frequency, LH secretion, and serum testosterone (George 2013, PMID 23153270), and IV kisspeptin restored GnRH-induced LH pulses in men who had reversed idiopathic hypogonadotropic hypogonadism (Lippincott 2016, PMID 27214398). These establish a biological effect over hours, not any durable clinical hypogonadism outcome; there are no efficacy RCTs, no chronic dosing data, and no oral/practical formulation. Emerging is the honest ceiling, at the earliest end of that band.

Anecdotal community signal (not proof): kisspeptin appears in research-peptide and biohacking circles marketed for libido and 'natural testosterone/HPG support,' sometimes injected subcutaneously. Reports are sparse and unreliable, product identity/purity is uncertain, and any perceived libido effect is uncontrolled anecdote; this is not a validated hypogonadism treatment and should not be presented as one.

Context, not a protocol: published human work used IV boluses (roughly 0.24-2.4 nmol/kg) or continuous infusion (~4 mcg/kg/h) in monitored research settings only. There is no established, safe self-administration regimen for hypogonadism; community peptide doses are arbitrary and unsupported.

Kisspeptin's action requires an intact, responsive GnRH neuron population, so it is inert where the hypothalamic-pituitary machinery is destroyed; responsiveness actually tracks with whether endogenous pulsatility exists. Continuous high-dose exposure can desensitize the axis (analogous to GnRH), meaning naive 'more is better' dosing could backfire. Research-grade/gray-market product carries real identity, purity, and sterility risks.

• Exploring the pathophysiology of hypogonadism in men with type 2 diabetes: kisspeptin-10 stimulates serum testosterone and LH secretion in men with type 2 diabetes and mild biochemical hypogonadism. ↗
• Kisspeptin Responsiveness Signals Emergence of Reproductive Endocrine Activity: Implications for Human Puberty. ↗